Cellular levels of class 1 and class 3 aldehyde dehydrogenases and certain other drug-metabolizing enzymes in human breast malignancies

Clinical Cancer Research

Volumn 3, Issue 11, 1997, Pages 1901-1914

  Sreerama, Lakshmaiah ^a   Sladek, Norman E ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DIHYDROLIPOAMIDE DEHYDROGENASE; GLUTATHIONE; GLUTATHIONE TRANSFERASE;

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CONTROLLED STUDY; DETOXIFICATION; DNA CROSS LINKING; DRUG SENSITIVITY; ENZYME ANALYSIS; ENZYME BINDING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; ALDEHYDE DEHYDROGENASE; BREAST; BREAST NEOPLASMS; CYTOCHROME P-450 CYP1A1; DIHYDROLIPOAMIDE DEHYDROGENASE; FEMALE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; MIDDLE AGED; NEOPLASM METASTASIS; REFERENCE VALUES; REGRESSION ANALYSIS; SMOKING;

EID: 0030721582     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Henderson, I. C. Adjuvant systemic therapy of early breast cancer. In: J. R. Harris, S. Hellman, I. C. Henderson, and D. W. Kinne (eds.), Breast Diseases, Ed. 2, pp. 427-486. Philadelphia: J. B. Lippincott, 1991.
2. Henderson, I. C. Chemotherapy for metastatic disease. In: J. R. Harris, S. Hellman, I. C. Henderson, and D. W. Kinne (eds.), Breast Diseases, Ed. 2, pp. 604-665. Philadelphia: J. B. Lippincott, 1991.
3. Davidson, N. E., and Abeloff, M. D. Adjuvant systemic therapy in women with early-stage breast cancer at high risk for relapse. J. Natl. Cancer Inst., 84: 301-305, 1992.
4. Triozzi, P. L., Rhoades, C., and Thornton, D. E. High-dose chemotherapy for breast cancer. Cancer Treat. Rev., 21: 185-198, 1995.
5. Sladek, N. E. Oxazaphosphorine-specific acquired cellular resistance. In: B. A. Teicher (ed.), Drug Resistance in Oncology, pp. 375-411. New York: Marcel Dekker, 1993.
6. Sladek, N. E. Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines. In: G. Powis (ed.), Anticancer Drugs: Reactive Metabolism and Drug Interactions, pp. 79-156. United Kingdom: Pergamon Press, 1994.
7. Sreerama, L., and Sladek, N. E. Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem. Pharmacol., 45: 2487-2505, 1993.
8. Sreerama, L., and Sladek, N. E. Overexpression or polycyclic aromatic hydrocarbon-mediated induction of an apparently novel class 3 aldehyde dehydrogenase in human breast adenocarcinoma cells and its relationship to oxazaphosphorine-specific acquired resistance. Adv. Exp. Med. Biol., 328: 99-113, 1993.
9. Sreerama, L., and Sladek, N. E. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Cancer Res., 54: 2176-2185, 1994.
10. Sreerama, L., and Sladek, N. E. Human breast adenocarcinoma MCF-7/0 cells electroporated with cytosolic class 3 aldehyde dehydrogenases obtained from tumor cells and normal tissue exhibit differential sensitivity to mafosfamide. Drug Metab. Dispos., 23: 1080-1084, 1995.
11. Bunting, K. D., Lindahl, R., and Townsend, A. J. Oxazaphosphorine-specific resistance in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase. J. Biol. Chem., 269: 23197-23203, 1994.
12. Rekha, G. K., Sreerama, L., and Sladek, N. E. Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase. Biochem. Pharmacol., 48: 1943-1952, 1994.
13. Sladek, N. E., Sreerama, L., and Rekha, G. K. Constitutive and overexpressed human cytosolic class-3 aldehyde dehydrogenases in normal and neoplastic cells/secretions. Adv. Exp. Med. Biol., 372: 103-114, 1995.
14. Sreerama, L., Rekha, G. K., and Sladek, N. E. Phenolic antioxidant-induced overexpression of class-3 aldehyde dehydrogenase and oxazaphosphorine-specific resistance. Biochem. Pharmacol., 49: 669-675, 1995.
15. Bunting, K. D., and Townsend, A. J. De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anti-cancer alkylating agents in hamster V79 cell lines. Elevated class 1 ALDH activity is closely correlated with reduction in DNA interstrand cross-linking and lethality. J. Biol. Chem., 271: 11884-11890, 1996.
16. Bunting, K. D., and Townsend, A. J. Protection by transfected rat or human class 3 aldehyde dehydrogenases against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. J. Biol. Chem., 271: 11891-11896, 1996.
17. Magni, M., Shammah, S., Schiró, R., Mellado, W., Dalla-Favera, R., and Gianni, A. M. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood, 87: 1097-1103, 1996.
18. Moreb, J., Schweder, M., Suresh, A., and Zucali, J. R. Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Ther., 3: 24-30, 1996.
19. Marselos, M., and Michalopoulos, G. Changes in the patterns of aldehyde dehydrogenase activity in primary and metastatic adenocarcinomas of the human colon. Cancer Lett., 34: 27-37, 1987.
20. Djuric, Z., Malviya, V. K., Deppe, G., Malone, J. M., Jr., McGunagle, D. L., Heilbrun, L. K., Reading, B. A., and Lawrence, W. D. Detoxifying enzymes in human ovarian tissues: comparison of normal and tumor tissues and effects of chemotherapy. J. Cancer Res. Clin. Oncol., 116: 379-383, 1990.
21. Sreerama, L., and Sladek, N. E. Over-expression of glutathione S-transferases, DT-diaphorase and an apparently tumor-specific cytosolic class-3 aldehyde dehydrogenase by Warthin tumors and mucoepidermoid carcinomas of the human parotid gland. Arch. Oral Biol., 41: 597-605, 1996.
22. Rekha, G. K., and Sladek, N. E. Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics. Cancer Chemother. Pharmacol., 40: 215-224, 1997.
23. Hainsworth, J. D. The use of mitoxantrone in the treatment of breast cancer. Semin. Oncol., 22 (Suppl. 1): 17-20, 1995.
24. Smitskamp-Wilms, E., Hendriks, H. R., and Peters, G. J. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. Gen. Pharmacol., 27: 421-429, 1996.
25. Sreerama, L., Hedge, M. W., and Sladek, N. E. Identification of a class 3 aldehyde dehydrogenase in human saliva and increased levels of this enzyme, glutathione S-transferases, and DT-diaphorase in the saliva of subjects who continually ingest large quantities of coffee or broccoli. Clin. Cancer Res., 1: 1153-1163, 1995.
26. Townsend, A. J., Goldsmith, M. E., Pickett, C. B., and Cowan, K. H. Isolation, characterization, and expression in Escherichia coli of two murine mu class glutathione S-transferase cDNAs homologous to the rat subunits 3 (Yb1) and 4 (Yb2). J. Biol. Chem., 264: 21582-21590, 1989.
27. Sreerama, L., and Sladek, N. E. Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents. Adv. Exp. Med. Biol., 414: 81-94, 1997.
28. Dockham, P. A., Lee, M-O., and Sladek, N. E. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem. Pharmacol., 43: 2453-2469, 1992.
29. Anderson, M. E. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol., 113: 548-555, 1985.
30. Schlager, J. J., and Powis, G. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int. J. Cancer, 45: 403-409 1990.
31. Murray, G. I., Weaver, R. J., Paterson, P. J., Ewen, S. W. B., Melvin, W. T., and Burke, M. D. Expression of xenobiotic metabolizing enzymes in breast cancer. J. Pathol., 169: 347-353, 1993.
32. Mulders, T. M. T., Keizer, H. J., Breimer, D. D., and Mulder, G. J. In vivo characterization and modulation of the glutathione/glutathione S-transferase system in cancer patients. Drug Metab. Rev., 27: 191-229, 1995.
33. 1-450 (CYP1A1) gene. Int. J. Biochem., 21: 243-252, 1989.
34. Rushmore, T. H., and Pickett, C. B. Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants. J. Biol. Chem., 265: 14648-14653, 1990.
35. Rushmore, T. H., King, R. G., Paulson, K. E., and Pickett, C. B. Regulation of glutathione S-transferase Ya subunit gene expression: identification of a unique xenobiotic-responsive element controlling inducible expression by planar aromatic compounds. Proc. Natl. Acad. Sci. USA, 87: 3826-3830, 1990.
36. Rushmore, T. H., Morton, M. R., and Pickett, C. B. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J. Biol. Chem., 266: 11632-11639, 1991.
37. Favreau, L. V., and Pickett, C. B. Transcriptional regulation of the rat NAD(P)H:quinone reductase gene. Identification of regulatory elements controlling basal level expression and inducible expression by planar aromatic compounds and phenolic antioxidants. J. Biol. Chem., 266: 4556-4561, 1991.
38. Li, Y., and Jaiswal, A. K. Regulation of human NAD(P)H:quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element. J. Biol. Chem., 207: 15097-15104, 1992.
39. Asman, D. C., Takimoto, K., Pitot, H. C., Dunn, T. J., and Lindahl, R. Organization and characterization of the rat class 3 aldehyde dehydrogenase gene. J. Biol. Chem., 268: 12530-12536, 1993.
40. 1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev., 12: 103-117, 1993.
41. Hayes, J. D., and Pulford, D. J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol., 30: 445-600, 1995.
42. El-Sharabasy, M. M. H., El-Dosoky, I., Horria, H., and Khalaf, A. H. Elevation of glutathione, glutathione-reductase and nucleic acids in both normal tissues and tumour of breast cancer patients. Cancer Lett., 72: 11-15, 1993.
43. Perry, R. R., Mazetta, J., Levin, M., and Barranco, S. C. Glutathione levels and variability in breast tumors and normal tissue. Cancer (Phila.), 72: 783-787, 1993.
44. Safe, S. H. Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Pharmacol. Ther., 67: 247-281, 1995.
45. O'Brien, M. L., and Tew, K. D. Glutathione and related enzymes in multidrug resistance. Eur. J. Cancer, 32A: 967-978, 1996.
46. Gosland, M., Lum, B., Schimmelpfennig, J., Baker J., and Doukas, M. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy, 16: 16-39, 1996.
47. Workman, P. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol. Res., 6: 461-475, 1994.
48. Paoletti, C., Lecointe, P., Lesca, P., Cros, S., Mansuy, D., and Dat Xuong, N. Metabolism of ellipticine and derivatives and its involvement in the antitumor action of these drugs. Biochimie, 60: 1003-1009, 1978.
49. Wolf, C. R., Macpherson, J. S., and Smyth, J. F. Evidence for the metabolism of mitozantrone by microsomal glutathione transferases and 3-methylcholanthrene-inducible glucuronosyl transferases. Biochem. Pharmacol., 35: 1577-1581, 1986.
50. Albin, N., Massaad, L., Toussaint, C., Mathieu, M-C., Morizet, J., Parise, O. Gouyette, A., and Chabot, G. G. Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res., 53: 3541-3546, 1993.
51. McVie, J. G., and Bonadonna, G. Paclitaxel (taxol): current practices and future directions in breast cancer management. Semin. Oncol., 23 (Suppl. 1): 1-68, 1996.
52. Rowinsky, E. K., Cazenave, L. A., and Donehower, R. C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst., 82: 1247-1259, 1990.
53. Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Shen, H-J., and Yang, C-P. H. Taxol: mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr., 15: 55-61, 1993.
54. Childs, S., and Ling, V. The MDR superfamily of genes and its biological implications. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Important Advances in Oncology, pp. 21-36. Philadelphia: J. B. Lippincott, 1994.
55. Goldstein, L. J. Clinical reversal of drug resistance. In: R. F. Ozols (ed.), Current Problems in Cancer, pp. 67-123. St. Louis: Mosby-Year Book, 1995.
56. Sanfilippo, O., Ronchi, E., De Marco, C., Di Fronzo, G., and Silvestrini, R. Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur. J. Cancer, 27: 155-158, 1991.
57. Charpin, C., Vielh, P., Duffaud, F., Devictor, B., Andrac, L., Lavaut, M. N., Allasia, C., Horschowski, N., and Piana, L. Quantitative immunocytochemical assays of P-glycoprotem in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J. Natl. Cancer Inst., 86: 1539-1545, 1994.
58. Filipits, M., Suchomel, R. W., Dekan, G., Haider, K., Valdimarsson G., Depisch, D., and Pirker, R. MRP and MDR1 gene expression in primary breast carcinomas. Clin. Cancer Res., 2: 1231-1237, 1996.
59. Sladek, N. E., Manthey, C. L., Maki, P. A., Zhang, Z., and Landkamer, G. J. Xenobiotic oxidation catalyzed by aldehyde dehydrogenases. Drug Metab. Rev., 20: 697-720, 1989.
60. Moreb, J. S., Turner, C., Sreerama, L., Zucali, J. R., Sladek, N. E., and Schweder, M. Interleukin-1 and tumor necrosis factor alpha induce class 1 aldehyde dehydrogenase mRNA and protein in bone marrow cells. Leukemia Lymphoma, 20: 77-84, 1995.
61. Rekha, G. K., and Sladek, N. E. Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol. Adv. Exp. Med. Biol., 414: 133-146, 1997.
62. Tso, W-W. Gossypol inhibits Ehrlich ascites tumor cell proliferation. Cancer Lett., 24: 257-261, 1984.
63. Wu, Y-W., Chik, C. L., and Knazek, R. A. An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenocortical carcinoma. Cancer Res., 49: 3754-3758, 1989.
64. Chang, C. J. G., Ghosh, P. K., Hu, Y. F., Brueggemeier, R. W. and Lin, Y. C. Antiproliferative and antimetastatic effects of gossypol on Dunning prostate cell-bearing Copenhagen rats. Res. Commun. Chem. Pathol. Pharmacol., 79: 293-312, 1993.
65. Naik, H. R., Petrylak, D., Yagoda, A., Lehr, J. E., Akhtar, A., and Pienta, K. J. Preclinical studies of gossypol in prostate carcinoma. Int. J. Oncol., 6: 209-213, 1995.
66. Stein, R. C., Joseph, A. E. A., Matlin, S. A., Cunningham, D. C., Ford, H. T., and Coombes, R. C. A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother. Pharmacol., 30: 480-482, 1992.
67. Flack, M. R., Pyle, R. G., Mullen, N. M., Lorenzo, B., Wu, Y. W., Knazek, R. A., Nisula, B. C., and Reidenberg, M. M. Oral gossypol in the treatment of metastatic adrenal cancer. J. Clin. Endocrinol. Metab., 76: 1019-1024, 1993.
68. Seidman, A. D. Chemotherapy for advanced breast cancer: a current perspective. Semin. Oncol., 23: 55-59, 1996.
69. Ross, A. A., Cooper, B. W., Lazarus, H. M., Mackay, W., Moss, T. J., Ciobanu, N., Tallman, M. S., Kennedy, M. J., Davidson, N. E., Sweet, D., Winter, C., Akard, L., Jansen, J., Copelan, E., Meagher, R. C., Herzig, R. H., Klumpp, T. R., Kahn, D. G., and Warner, N. E. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood, 82: 2605-2610, 1993.
70. Datta, Y. H., Adams, P. T., Drobyski, W. R., Ethier, S. P., Terry, V. H., and Roth, M. S. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J. Clin. Oncol., 12: 475-482, 1994.
71. Kennedy, M. J., Beveridge, R. A., Rowley, S. D., Gordon, G. B., Abeloff, M. D., and Davidson, N. E. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J. Natl. Cancer Inst., 83: 920-926, 1991.
72. Shpall, E. J., Jones, R. B., Bast, R. C., Jr., Rosner, G. L., Vandermark, R., Ross, M., Affronti, M. L., Johnston, C., Eggleston, S., Tepperburg, M., Coniglio, D., and Peters, W. P. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a Phase I trial. J. Clin. Oncol., 9: 85-93, 1991.
73. Griffith, O. W., and Meister, A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem., 254: 7558-7560, 1979.
74. O'Dwyer, P. J., Hamilton, T. C., Yao, K-S., Tew, K. D., and Ozols, R. F. Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs. Hematol. Oncol. Clin. N. Am., 9: 383-396, 1995.
75. O'Dwyer, P. J., Hamilton, T. C., LaCreta, F. P., Gallo, J. M., Kilpatrick, D., Halbherr, T., Brennan, J., Bookman, M. A., Hoffman, J., Young, R. C., Comis, R. L., and Ozols, R. F. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer J. Clin. Oncol., 14: 249-256, 1996.